263 related articles for article (PubMed ID: 29556365)
1. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.
Lin L; Fan Y; Gao F; Jin L; Li D; Sun W; Li F; Qin P; Shi Q; Shi X; Du L
Theranostics; 2018; 8(7):1923-1939. PubMed ID: 29556365
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy.
Li Y; Chen Y; Li J; Zhang Z; Huang C; Lian G; Yang K; Chen S; Lin Y; Wang L; Huang K; Zeng L
Cancer Sci; 2017 Jul; 108(7):1493-1503. PubMed ID: 28444967
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer.
Nesbitt H; Sheng Y; Kamila S; Logan K; Thomas K; Callan B; Taylor MA; Love M; O'Rourke D; Kelly P; Beguin E; Stride E; McHale AP; Callan JF
J Control Release; 2018 Jun; 279():8-16. PubMed ID: 29653222
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of VEGFR2-targeted microbubble destruction with gemcitabine using an endoscopic ultrasound probe: In vivo mouse pancreatic ductal adenocarcinoma model.
Shimamoto N; Ito M; Chiba M; Honma S; Imazu H; Sumiyama K
Hepatobiliary Pancreat Dis Int; 2020 Oct; 19(5):478-485. PubMed ID: 32265136
[TBL] [Abstract][Full Text] [Related]
6. Zwitterion-functionalized dendrimer-entrapped gold nanoparticles for serum-enhanced gene delivery to inhibit cancer cell metastasis.
Xiong Z; Alves CS; Wang J; Li A; Liu J; Shen M; Rodrigues J; Tomás H; Shi X
Acta Biomater; 2019 Nov; 99():320-329. PubMed ID: 31513912
[TBL] [Abstract][Full Text] [Related]
7. Biodegradable, pH-Sensitive Hollow Mesoporous Organosilica Nanoparticle (HMON) with Controlled Release of Pirfenidone and Ultrasound-Target-Microbubble-Destruction (UTMD) for Pancreatic Cancer Treatment.
Gao F; Wu J; Niu S; Sun T; Li F; Bai Y; Jin L; Lin L; Shi Q; Zhu LM; Du L
Theranostics; 2019; 9(20):6002-6018. PubMed ID: 31534533
[TBL] [Abstract][Full Text] [Related]
8. Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer.
Uz M; Kalaga M; Pothuraju R; Ju J; Junker WM; Batra SK; Mallapragada S; Rachagani S
J Control Release; 2019 Jan; 294():237-246. PubMed ID: 30576747
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
10. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
[TBL] [Abstract][Full Text] [Related]
11. Gene delivery using dendrimer-entrapped gold nanoparticles as nonviral vectors.
Shan Y; Luo T; Peng C; Sheng R; Cao A; Cao X; Shen M; Guo R; Tomás H; Shi X
Biomaterials; 2012 Apr; 33(10):3025-35. PubMed ID: 22248990
[TBL] [Abstract][Full Text] [Related]
12. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
13. A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy.
Qiu W; Zhang H; Chen X; Song L; Cui W; Ren S; Wang Y; Guo K; Li D; Chen R; Wang Z
Nanomedicine (Lond); 2019 Sep; 14(17):2339-2353. PubMed ID: 31414945
[No Abstract] [Full Text] [Related]
14. A tumor microenvironment-stimuli responsive nano-prodrug for overcoming gemcitabine chemoresistance by co-delivered miRNA-21 modulator.
Zhang F; Yao Z; Jin P; Xu M; Hu Q; Chen Y; Que R; Liang T
Biomed Mater; 2023 Apr; 18(3):. PubMed ID: 36990101
[TBL] [Abstract][Full Text] [Related]
15. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers.
Öztürk K; Esendağlı G; Gürbüz MU; Tülü M; Çalış S
Int J Pharm; 2017 Jan; 517(1-2):157-167. PubMed ID: 27965135
[TBL] [Abstract][Full Text] [Related]
16. Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment.
Han H; Wang J; Chen T; Yin L; Jin Q; Ji J
J Colloid Interface Sci; 2017 Dec; 507():217-224. PubMed ID: 28800445
[TBL] [Abstract][Full Text] [Related]
17. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
[TBL] [Abstract][Full Text] [Related]
18. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
Mondal G; Almawash S; Chaudhary AK; Mahato RI
Mol Pharm; 2017 Sep; 14(9):3121-3133. PubMed ID: 28719220
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer.
Li YJ; Wu JY; Wang JM; Hu XB; Cai JX; Xiang DX
Acta Biomater; 2020 Jan; 101():519-530. PubMed ID: 31629893
[TBL] [Abstract][Full Text] [Related]
20. Partially Acetylated Dendrimer-Entrapped Gold Nanoparticles with Reduced Cytotoxicity for Gene Delivery Applications.
Hou W; Wen S; Guo R; Wang S; Shi X
J Nanosci Nanotechnol; 2015 Jun; 15(6):4094-105. PubMed ID: 26369017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
